Group 1 - KJ International (06822.HK) sold a total of 4,114,080 shares of China Construction Bank at an average price of approximately HKD 7.21 per share, totaling around HKD 29,663,000 excluding transaction costs [1] - High雅光学 (00907.HK) plans to establish different subsidiaries to engage in liquor, eyewear, and gold jewelry-related businesses [1] - Southern Manganese (01091.HK) aims to reduce group liabilities by HKD 300 million to HKD 500 million annually over the next five years [1] Group 2 - Stone Four Pharmaceutical Group (02005.HK) obtained the drug production registration certificate for calcium gluconate and sodium chloride injection (100ml) from the National Medical Products Administration [2] - Yanda Pharmaceutical (00512.HK) completed patient enrollment for the international multi-center Phase III clinical trial of the global innovative ophthalmic drug CBT-001 [2] - Zhaoke Ophthalmology-B (06622.HK) received FDA approval for the new drug trial application for cyclosporine eye gel [2] Group 3 - Anta Sports (02020.HK) granted a total of approximately 10.45 million reward shares [3] - Tencent Holdings (00700.HK) repurchased 980,000 shares at a cost of HKD 500 million on June 4 [3] - AIA Group (01299.HK) repurchased 3.25 million shares at a cost of HKD 215 million on June 4 [3]

Core Viewpoint - Stone Four Pharmaceutical Group has obtained the drug production registration certificate for Calcium Gluconate and Sodium Chloride Injection (100ml), which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Calcium Gluconate and Sodium Chloride Injection is primarily used for the treatment of acute hypocalcemia, magnesium poisoning, and fluoride poisoning [1]